Figure 7.

A preclinical NSCLC mouse model was reversed by dual treatment with BPTES and 5-FU. (a) A549-luciferase (5 × 10⁶) cells were injected in both flanks of 6–8-week-old BALB/c nude mice. When the volume of the tumour mass reached 80 mm³, the mice were randomly assigned to one of four treatment groups including vehicle control, BPTES, 5-FU and combination of BPTES and 5-FU (n=10 per group). BPTES (10 mg/kg body weight), 5-FU (20 mg/kg body weight), and vehicle were administered orally 5 days/week, and the tumour growth was monitored by photon flux released from luciferin as described in the experimental procedures. The data were expressed as photon flux (photons/s/cm²/steradian), which is represented by a colour scale. (b) Graph shows the total ROI value. (c) Graph represents the tumour growth curve as measured using calipers. (d) A proposed model of the synergistic mechanism between GLS1 inhibition and TYMS inhibition in NSCLC. P-values were determined using two-tailed Student's t-tests (ns, not significant; *0.01<P<0.05; P<0.01; ***P<0.001)